© 2004 BMJ Publishing Group Ltd & Association of Clinical Pathologists
ORIGINAL ARTICLE
Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in Israel
1 Department of Oncology, Rambam Medical Centre and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel
2 Department of Pathology, Rambam Medical Centre and Faculty of Medicine
3 Department of Otolaryngology, Rambam Medical Centre and Faculty of Medicine
Correspondence to:
Correspondence to:
Dr G Bar-Sela
Department of Oncology, Rambam Medical Centre, PO Box 9602, Haifa 31096 Israel; g\|[lowbar]\|barsela{at}rambam.health.gov.il
Background: Nasopharyngeal carcinoma (NPC) is frequently associated with Epstein-Barr virus (EBV). The incidence of NPC in Western countries is lower than in the Far East, and EBV latency in NPC is less prevalent. Israel, as a part of the Mediterranean area, is one of the countries with an intermediate risk for NPC.
Methods: Immunohistochemistry (IHC) for latent membrane protein 1 (LMP-1) and in situ hybridisation (ISH) for EBV encoded RNA (EBER) were used to evaluate the prevalence and possible prognostic value of EBV latency among Israeli patients with NPC. Forty five patients with different NPC histologies were studied.
Results: LMP-1 IHC was positive in six samples only, all with undifferentiated histology. EBER ISH was positive in 40 of the 45 samples. According to histological type, three of five patients with squamous cell carcinoma were EBV positive and 37 of 40 non-keratinising and undifferentiated carcinoma cases were positive. Although EBV was more prevalent in patients with non-squamous carcinoma, the difference was not significant, probably because of the small number of patients with keratinising carcinoma. With regard to the clinical categories and survival, no significant difference could be detected between patients who were positive or negative for EBER ISH. No association was found between EBV latency and patient sex, age, origin, stage, or survival.
Conclusions: NPC in Israel is highly associated with EBV latency as detected by EBER ISH. LMP-1 IHC is considerably less sensitive in detecting EBV latency in NPC among the same patient group.
Keywords: Epstein-Barr virus; nuclear Epstein-Barr virus encoded RNA in situ hybridisation; nasopharyngeal carcinoma
Abbreviations: AJCC, American Joint Committee of Cancer; EBER, nuclear Epstein-Barr virus encoded RNA; EBV, Epstein-Barr virus; IHC, immunohistochemistry; ISH, in situ hybridisation; LMP-1, latent membrane protein 1; NPC, nasopharyngeal carcinoma; WHO, World Health Organisation
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Kalpoe, J S, Douwes Dekker, P B, van Krieken, J H J M, Baatenburg de Jong, R J, Kroes, A C M
(2006). Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area. J. Clin. Pathol.
59: 537-541
[Abstract] [Full Text] -
Tan, K-B, Putti, T C
(2005). Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J. Clin. Pathol.
58: 535-538
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
